Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19

Article activity feed

1. Version published to 10.1038/s41593-020-00758-5

   Nov 30, 2020
2. 

   ScreenIT

   Jun 9, 2020

   SciScore for 10.1101/2020.06.04.135012: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IRB: This study was approved by the Ethics Committee of the Charité (EA 1/144/13 and EA2/066/20) as well as by the Charité-BIH COVID-19 research board and was in compliance with the Declaration of Helsinki.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   The following primary antibodies were used: monoclonal mouse anti-S100 (DAKO Z0311,	anti-S100 suggested: (Agilent Cat# Z0311, RRID:AB_10013383)
   mouse monoclonal anti-SARS spike glycoprotein antibody (Abcam, ab272420, 1:100, pretreatment Citrate + MW) and polyclonal rabbit anti-OLIG2 (IBL, 18953, 1:150, …

   SciScore for 10.1101/2020.06.04.135012: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IRB: This study was approved by the Ethics Committee of the Charité (EA 1/144/13 and EA2/066/20) as well as by the Charité-BIH COVID-19 research board and was in compliance with the Declaration of Helsinki.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   The following primary antibodies were used: monoclonal mouse anti-S100 (DAKO Z0311,	anti-S100 suggested: (Agilent Cat# Z0311, RRID:AB_10013383)
   mouse monoclonal anti-SARS spike glycoprotein antibody (Abcam, ab272420, 1:100, pretreatment Citrate + MW) and polyclonal rabbit anti-OLIG2 (IBL, 18953, 1:150, pretreatment Tris-EDTA + MW).	anti-SARS spike glycoprotein antibody ( Abcam , ab272420 suggested: None anti-OLIG2 suggested: (Immuno-Biological Laboratories Cat# 18953, RRID:AB_2267671)
   Briefly, primary antibodies were applied and developed either using the iVIEW DAB Detection Kit (Ventana Medical Systems) and the ultraView Universal Alkaline Phosphatase Red Detection Kit (Ventana Medical Systems) or by manual application of biotinylated secondary antibodies (Merck, RPN1001, RPN1004)	RPN1001 suggested: (GE Healthcare Cat# RPN1001-2ML, RRID:AB_1062579) RPN1004 suggested: (GE Healthcare Cat# RPN1004-2ML, RRID:AB_1062582)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
3. 

   Version published to 10.1101/2020.06.04.135012v1 on bioRxiv

   Jun 4, 2020